VSTM - ベラステム (Verastem Inc.)

VSTMのニュース

   The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx  2021/04/29 12:15:49 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ: AXNX ) Boston Scientific Corporation (NYSE: BSX ) (reacted to first-quarter results) Celcuity Inc. (NASDAQ: CELC ) Celldex Therapeutics, Inc. (NASDAQ: CLDX) Galectin Therapeutics Inc. (NASDAQ: GALT ) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Insulet Corporation (NASDAQ: PODD ) Integra LifeSciences Holdings Corporation (NASDAQ: IART ) (announced first-quarter results) Lantheus Holdings, Inc. (NASDAQ: LNTH ) MacroGenics, Inc. (NASDAQ: MGNX ) NuVasive, Inc. (NASDAQ: NUVA) PRA Health Sciences, Inc. (NASDAQ: PRAH ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Verastem, Inc. (NASDAQ: VSTM ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 28) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Decibel Therapeutics, Inc. (NASDAQ: DBTX ) IRadimed Corporation (NASDAQ: IRMD ) Lucira Health, Inc. (NASDAQ: LHDX ) Mesoblast Limited (NASDAQ: MESO ) Protara Therapeutics, Inc. (NASDAQ: TARA ) PTC Therapeutics, Inc. (NASDAQ: PTCT ) Stocks In Focus Adverum Shares Sink On Serious Adverse Event Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) announced a suspected unexpected serious adverse reaction of hypotony, which is clinically relevant decrease in ocular pressure, in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema.
   News briefing: Verastem CMO exits two weeks after joining company; Thermo Fisher inks $550M M&A deal  2021/01/20 16:02:15 Endpoints News
Two weeks after joining Verastem Oncology as chief medical officer, Frank Neumann is leaving the company for another job. Neumann had joined Verastem after leaving bluebird bio, which surprisingly split into two companies last week, one in oncology and one in rare diseases. It’s not yet clear to where Neumann
   Roller coaster ride for Verastem continues as 2 weeks into the job, its CMO quits  2021/01/20 14:50:39 FierceBiotech
After selling off its marketed cancer drug and focusing back on its pipeline after the loss of its CEO in 2019, Verastem started 2021 looking for stability in a new chief medical officer.
   Verastem : Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | MarketScreener  2021/01/07 21:07:02 MarketScreener
Verastem, Inc. , a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the grant of options to purchase 86,250 shares of its common stock and… | January 7, 2021
   Verastem, Inc. (NASDAQ:VSTM) Short Interest Down 13.5% in September  2020/10/22 06:45:00 Stock Observer
Verastem, Inc. (NASDAQ:VSTM) was the target of a large decline in short interest in September. As of September 30th, there was short interest totalling 10,070,000 shares, a decline of 13.5% from the September 15th total of 11,640,000 shares. Based on an average daily volume of 4,060,000 shares, the short-interest ratio is currently 2.5 days. Several […]
   The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx  2021/04/29 12:15:49 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ: AXNX ) Boston Scientific Corporation (NYSE: BSX ) (reacted to first-quarter results) Celcuity Inc. (NASDAQ: CELC ) Celldex Therapeutics, Inc. (NASDAQ: CLDX) Galectin Therapeutics Inc. (NASDAQ: GALT ) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Insulet Corporation (NASDAQ: PODD ) Integra LifeSciences Holdings Corporation (NASDAQ: IART ) (announced first-quarter results) Lantheus Holdings, Inc. (NASDAQ: LNTH ) MacroGenics, Inc. (NASDAQ: MGNX ) NuVasive, Inc. (NASDAQ: NUVA) PRA Health Sciences, Inc. (NASDAQ: PRAH ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Verastem, Inc. (NASDAQ: VSTM ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 28) Akoya Biosciences, Inc. (NASDAQ: AKYA ) Decibel Therapeutics, Inc. (NASDAQ: DBTX ) IRadimed Corporation (NASDAQ: IRMD ) Lucira Health, Inc. (NASDAQ: LHDX ) Mesoblast Limited (NASDAQ: MESO ) Protara Therapeutics, Inc. (NASDAQ: TARA ) PTC Therapeutics, Inc. (NASDAQ: PTCT ) Stocks In Focus Adverum Shares Sink On Serious Adverse Event Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) announced a suspected unexpected serious adverse reaction of hypotony, which is clinically relevant decrease in ocular pressure, in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema.
   News briefing: Verastem CMO exits two weeks after joining company; Thermo Fisher inks $550M M&A deal  2021/01/20 16:02:15 Endpoints News
Two weeks after joining Verastem Oncology as chief medical officer, Frank Neumann is leaving the company for another job. Neumann had joined Verastem after leaving bluebird bio, which surprisingly split into two companies last week, one in oncology and one in rare diseases. It’s not yet clear to where Neumann
   Roller coaster ride for Verastem continues as 2 weeks into the job, its CMO quits  2021/01/20 14:50:39 FierceBiotech
After selling off its marketed cancer drug and focusing back on its pipeline after the loss of its CEO in 2019, Verastem started 2021 looking for stability in a new chief medical officer.
   Verastem : Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | MarketScreener  2021/01/07 21:07:02 MarketScreener
Verastem, Inc. , a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the grant of options to purchase 86,250 shares of its common stock and… | January 7, 2021
   Verastem, Inc. (NASDAQ:VSTM) Short Interest Down 13.5% in September  2020/10/22 06:45:00 Stock Observer
Verastem, Inc. (NASDAQ:VSTM) was the target of a large decline in short interest in September. As of September 30th, there was short interest totalling 10,070,000 shares, a decline of 13.5% from the September 15th total of 11,640,000 shares. Based on an average daily volume of 4,060,000 shares, the short-interest ratio is currently 2.5 days. Several […]
   News briefing: Verastem CMO exits two weeks after joining company; Thermo Fisher inks $550M M&A deal  2021/01/20 16:02:15 Endpoints News
Two weeks after joining Verastem Oncology as chief medical officer, Frank Neumann is leaving the company for another job. Neumann had joined Verastem after leaving bluebird bio, which surprisingly split into two companies last week, one in oncology and one in rare diseases. It’s not yet clear to where Neumann
   Roller coaster ride for Verastem continues as 2 weeks into the job, its CMO quits  2021/01/20 14:50:39 FierceBiotech
After selling off its marketed cancer drug and focusing back on its pipeline after the loss of its CEO in 2019, Verastem started 2021 looking for stability in a new chief medical officer.
   Verastem : Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | MarketScreener  2021/01/07 21:07:02 MarketScreener
Verastem, Inc. , a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the grant of options to purchase 86,250 shares of its common stock and… | January 7, 2021
   Verastem, Inc. (NASDAQ:VSTM) Short Interest Down 13.5% in September  2020/10/22 06:45:00 Stock Observer
Verastem, Inc. (NASDAQ:VSTM) was the target of a large decline in short interest in September. As of September 30th, there was short interest totalling 10,070,000 shares, a decline of 13.5% from the September 15th total of 11,640,000 shares. Based on an average daily volume of 4,060,000 shares, the short-interest ratio is currently 2.5 days. Several […]
   Verastem, Inc. (NASDAQ:VSTM) Sees Large Drop in Short Interest  2020/10/21 06:44:46 Zolmax News
Verastem, Inc. (NASDAQ:VSTM) was the recipient of a large decline in short interest in September. As of September 30th, there was short interest totalling 10,070,000 shares, a decline of 13.5% from the September 15th total of 11,640,000 shares. Based on an average daily volume of 4,060,000 shares, the days-to-cover ratio is currently 2.5 days. Large […]

calendar